Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) lost $3.71 (31%) to $8.31 Thursday after the company reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter syndrome) and SB-318 to treat

Read the full 455 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE